EBITDA: Income before interest, taxes, depreciation and amortization.
Atea Pharmaceuticals, Inc. (AVIR) had EBITDA of $-35.54M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-32.93M |
|
-- |
|
-- |
|
$35.10M |
|
$-35.10M |
|
$2.19M |
|
$-32.91M |
|
$-32.91M |
|
$-32.93M |
|
$-32.93M |
|
$-32.93M |
|
$-32.93M |
|
$-35.10M |
|
|
EBITDA |
$-35.54M |
80.05M |
|
80.05M |
|
$-0.41 |
|
$-0.41 |
|
| Balance Sheet Financials | |
$228.66M |
|
$0.25M |
|
$3.62M |
|
$232.28M |
|
$28.12M |
|
-- |
|
-- |
|
$28.12M |
|
$204.16M |
|
$204.16M |
|
$204.16M |
|
80.20M |
|
| Cash Flow Statement Financials | |
$-83.47M |
|
$64.05M |
|
$0.26M |
|
$95.71M |
|
$76.55M |
|
$-19.16M |
|
$7.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.13 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-83.47M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.13% |
|
-16.13% |
|
-14.18% |
|
-16.13% |
|
$2.55 |
|
$-1.04 |
|
$-1.04 |
|